The benefits of our lead products are targeted at helping ADHD patients and their families improve the quality of their lives by leveraging proprietary technologies to address a significant unmet medical need – the lack of control of symptoms of ADHD during the morning routine.
A majority of surveyed families report ADHD symptoms as ‘severe’ or ‘moderate-to-severe’ during the morning routine – the period immediately upon waking until the patient leaves for work or school. This period is often the busiest and most chaotic for families.
Highland Therapeutics, through its wholly owned subsidiary Ironshore Pharmaceuticals & Development, Inc., has developed a proprietary, oral controlled-release technology that enables evening dosing of medication with delayed and extended release characteristics that provide for next-day therapeutic activity beginning in the early morning and lasting throughout the day.
Highland Therapeutics Inc. is a client of MaRS Discovery District’s Health Venture Services group, which provides advisory services, connections to talent, customer & capital networks, and market intelligence to high-impact, Ontario-based life sciences ventures, helping them commercialize their ideas and build globally competitive companies.
South Tower, Suite 310
101 College St.
Toronto, ON, Canada
Follow us on LinkedIn:
Email (all fields required)